Drug Profile
Research programme: liver X receptor modulators - AbbVie
Alternative Names: VTP 38443; VTP-4Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Vitae Pharmaceuticals
- Developer AbbVie; Vitae Pharmaceuticals
- Class Small molecules
- Mechanism of Action Liver X receptor agonists; Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute coronary syndromes
- Discontinued Alzheimer's disease; Atherosclerosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Jan 2019 No recent reports of development identified for preclinical development in Acute coronary syndromes in USA (PO)
- 31 Mar 2015 Vitae Pharmaceuticals plans a phase I trial for VTP 38443 in acute coronary syndrome